BUSINESS SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2013

Segment Reporting [Abstract]

Business Segment Information [Text Block]

Note 2. BUSINESS SEGMENT INFORMATION

BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are utilized and responsible for the development and delivery of products to the market. Regional commercial organizations are used to distribute and sell the product. The business is also supported by global corporate staff functions. Segment information is consistent with the financial information regularly reviewed by the chief executive officerfor purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods.

Net sales of key products were as follows:

		Three Months Ended March 31,
Dollars in Millions		2013		2012
Virology
Baraclude (entecavir)		$	366	$	325
Reyataz (atazanavir sulfate)			361		358
Sustiva (efavirenz) Franchise			387		386
Oncology
Erbitux* (cetuximab)			162		179
Sprycel (dasatinib)			287		231
Yervoy (ipilimumab)			229		154
Neuroscience
Abilify* (aripiprazole)			522		621
Metabolics
Bydureon* (exenatide extended-release for injectable suspension)			52		N/A
Byetta* (exenatide)			85		N/A
Forxiga (dapagliflozin)			3		N/A
Onglyza/Kombiglyze (saxagliptin/saxagliptin and metformin)			202		161
Immunoscience
Nulojix (belatacept)			5		1
Orencia (abatacept)			320		254
Cardiovascular
Avapro*/Avalide* (irbesartan/irbesartan-hydrochlorothiazide)			46		207
Eliquis (apixaban)			22		-
Plavix* (clopidogrel bisulfate)			91		1,693
Mature Products and All Other			691		681
	Net Sales	$	3,831	$	5,251

*       Indicates brand names of products which are trademarks not owned or wholly owned by BMS. Specific trademark ownership information can be found at the end of this quarterly report on Form 10-Q.